Institut de Recherche Servier

Institut de Recherche Servier is the primary research and development arm of Servier, a global independent pharmaceutical group governed by a non-profit foundation. Headquartered in France, the institute focuses on five main therapeutic areas: oncology, cardiovascular and metabolic diseases, immuno-inflammation, and neuro-psychiatric disorders. A major milestone for the organization was the 2023 opening of the Servier Research and Development Center at the Paris-Saclay innovation cluster, designed to accelerate drug discovery through collaborative research. The institute maintains a robust pipeline of small molecules and biologics, with a significant emphasis on precision medicine in oncology, exemplified by its work on IDH inhibitors and MCL-1 antagonists.